Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Nov 12

    Regeneron Announces Upcoming Investor Conference Presentations
  • Nov 06

    Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting


  • Piper Jaffray 31st Annual Healthcare Conference
    Dec 3
    8:00 AM EST
    Dec 3, 2019 | 8:00 AM EST

  • Jefferies 2019 London Healthcare Conference
    Nov 20
    9:00 AM EST
    Nov 20, 2019 | 9:00 AM EST

  • Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day
    Nov 18
    11:15 AM EST
    Nov 18, 2019 | 11:15 AM EST